A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection (GS-US-528-9023)

Study category: Immune System and Allergy

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Prevention

Scope

National

Locations

Outpatient CTRC

Principal Investigator
Thomas Campbell,  MD

Thomas Campbell, MD

Study ID

Protocol Number: 21-3252

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers